Receptor News and Research

RSS

Opportunity for developers and marketers of EGFR inhibitors in Brazil and Mexico

Decision Resources, one of the world's leading research and advisory firms for pharmaceutical and healthcare issues, finds that patient access to premium-priced targeted cancer treatments in Brazil and Mexico is improving, creating an opportunity for developers and marketers of epidermal growth factor receptor (EGFR) inhibitors.

5 Apr 2012

ARI-4175 drug may treat colorectal cancer patients with KRAS mutation

When combined with other treatments, the drug cetuximab-which works by slowing or stopping the growth of cancer cells-has been shown to extend survival in certain types of cancer, including metastatic colorectal cancers. Unfortunately, about 40 percent of colorectal cancer patients-specifically those who carry a mutated form of a gene called KRAS-do not respond to the drug. Researchers at Fox Chase Cancer Center in Philadelphia, however, have been working on a way to overcome this resistance to cetuximab by unleashing a second cetuximab driven mechanism using a novel drug called ARI-4175.

5 Apr 2012

VCAM1 nanobodies can effectively visualize atherosclerotic lesions

In collaboration with a Brussels University team under the leadership of Nick Devoogdt and a French team from INSERM, Serge Muyldermans and his team, associated with VIB and Vrije Universiteit Brussel, have succeeded in developing the first patient-friendly, non-invasive method for differentiating dangerous strictures in blood vessels, so-called vulnerable atherosclerotic plaques, from less dangerous ones.

5 Apr 2012

Olanzapine improves survival in mouse model of anorexia nervosa

Low doses of a commonly used atypical antipsychotic drug improved survival in a mouse model of anorexia nervosa, University of Chicago researchers report this month. The result offers promise for a common and occasionally fatal eating disorder that currently lacks approved drugs for treatment.

5 Apr 2012

Drugs that target cholesterol pathway may enhance cancer-killing potential of chemotherapy drugs

Johns Hopkins investigators are testing a way to use drugs that target a cholesterol pathway to enhance the cancer-killing potential of standard chemotherapy drugs. Their tests, in mouse models of pancreatic cancer, may yield new and more effective combinations of current and possibly new anti-cancer drugs.

4 Apr 2012

Researchers identify how neural cells build up resistance to opioid pain drugs within hours

Researchers at the University of Montreal's Sainte-Justine Hospital have identified how neural cells are able to build up resistance to opioid pain drugs within hours. "A better understanding of these mechanisms will enable us to design drugs that avoid body resistance to these drugs and produce longer therapeutic responses, including prolonged opioid analgesia", lead author Dr. Graciela Pineyro said.

4 Apr 2012

Positive preclinical results from Cancer Therapeutics' CTX-0294945 plus Avastin study

Cancer Therapeutics, a company focused on translating cancer biology research into novel treatments for cancer, today announced positive preclinical results for CTX-0294945 as an adjuvant therapy to the cancer drug Avastin (bevacizumab - Genentech/Roche). The data is presented today in a late breaking poster at the American Association for Cancer Research (AACR) Annual Meeting 2012 in Chicago, USA.

4 Apr 2012

Removing SR-BI receptor may help protect against breast cancer

Removing a lipoprotein receptor known as SR-BI may help protect against breast cancer, as suggested by new findings presented at the American Association for Cancer Research Annual Meeting 2012 by Jefferson's Kimmel Cancer Center researchers.

4 Apr 2012

BioScale presents data on phospho-protein analysis of MAP kinase pathway activation state at 103rd AACR

BioScale, Inc. a life science company that develops ultrasensitive protein analysis technology, presented findings of recently completed research studies on phospho-protein analysis of the activation state of the MAP kinase pathway at the 103rd Annual Meeting of the American Association for Cancer Research (AACR), held at McCormick Place in Chicago, Illinois, March 31 - April 4, 2012.

3 Apr 2012

Lilly announces results of three preclinical studies that focus on c-MET receptor

Eli Lilly and Company today announced results of three preclinical studies focused on c-MET, a receptor tyrosine kinase that, when it functions normally, plays a key role in transmitting signals within a cell.

3 Apr 2012

Study shows how morphine creates inflammatory response in the brain

An international team of researchers involving the University of Adelaide and University of Colorado has made a major discovery that could lead to more effective treatment of severe pain using morphine.

3 Apr 2012

TLR4/MD-2 protein complex triggers morphine-induced inflammation

A University of Colorado Boulder-led research team has discovered that two protein receptors in the central nervous system team up to respond to morphine and cause unwanted neuroinflammation, a finding with implications for improving the efficacy of the widely used painkiller while decreasing its abuse potential.

3 Apr 2012

New data demonstrates anti-cancer activities of Oncoprex

New data demonstrating the anti-cancer activities of Oncoprex were presented at the 2012 Annual Meeting of the American Association for Cancer Research (AACR) in Chicago, IL. The study, "Synergistic antitumor activity of AKT inhibitor MK2206 and FUS1 nanoparticles in LKB1 mutant NSCLC" (Meng J, Lara-Guerra H, Ji L, Roth JA) is authored by a team of investigators from The University of Texas MD Anderson Cancer Center.

3 Apr 2012

New preclinical data on ARIAD's ponatinib and AP26113 study presented at AACR meeting

ARIAD Pharmaceuticals, Inc. today announced the presentation of new preclinical data on its investigational pan-BCR-ABL inhibitor, ponatinib, and its investigational dual EGFR-ALK inhibitor, AP26113, at the American Association for Cancer Research Annual Meeting in Chicago.

3 Apr 2012

Scientists use DNA sequencing to identify 'driver' mutations in cancer

Scientists at Washington University School of Medicine in St. Louis are using powerful DNA sequencing technology not only to identify mutations at the root of a patient's tumor - considered key to personalizing cancer treatment - but to map the genetic evolution of disease and monitor response to treatment.

2 Apr 2012

Study confirms link between breast cancer and autoimmune arthritis

New research shows it may be no accident when doctors observe how patients suffering from both breast cancer and arthritis seem to have more aggressive cancer. However, the new-found interaction between the two diseases may also suggest a possible treatment.

2 Apr 2012

Galeterone safe, effective for patients with CRPC

Patients with castration-resistant prostate cancer had limited side effects and in many cases a drop in prostate-specific antigen expression with galeterone (TOK-001), a small-molecule oral drug, according to phase I data presented at the AACR Annual Meeting 2012, held here March 31 - April 4.

2 Apr 2012

Combination of cixutumumab and temsirolimus shrinks tumors in patients with Ewing's sarcoma

A pair of targeted therapies shrank tumors in some patients with treatment-resistant Ewing's sarcoma or desmoplastic small-round-cell tumors, according to research led by investigators from The University of Texas MD Anderson Cancer Center reported at the AACR Annual Meeting 2012.

2 Apr 2012

Platelet activating factor plays a crucial role in development of graft-versus-host disease

A new discovery in mice may lead to new treatments that could make bone marrow transplants more likely to succeed and to be significantly less dangerous.

2 Apr 2012

STAT-1 and PLSCR-1 proteins could play a crucial role in breast cancer

At the time of diagnosis, the majority of breast cancers are categorized as estrogen-receptor positive, or hormone sensitive, which means their cancerous cells may need estrogen to grow. Patients with this type of cancer often respond favorably to treatments called aromatase inhibitors, like tamoxifen, which cause cell death by preventing estrogen from reaching the cancerous cells.

2 Apr 2012

Receptor News and Research

Opportunity for developers and marketers of EGFR inhibitors in Brazil and Mexico

ARI-4175 drug may treat colorectal cancer patients with KRAS mutation

VCAM1 nanobodies can effectively visualize atherosclerotic lesions

Olanzapine improves survival in mouse model of anorexia nervosa

Drugs that target cholesterol pathway may enhance cancer-killing potential of chemotherapy drugs

Researchers identify how neural cells build up resistance to opioid pain drugs within hours

Positive preclinical results from Cancer Therapeutics' CTX-0294945 plus Avastin study

Removing SR-BI receptor may help protect against breast cancer

BioScale presents data on phospho-protein analysis of MAP kinase pathway activation state at 103rd AACR

Lilly announces results of three preclinical studies that focus on c-MET receptor

Study shows how morphine creates inflammatory response in the brain

TLR4/MD-2 protein complex triggers morphine-induced inflammation

New data demonstrates anti-cancer activities of Oncoprex

New preclinical data on ARIAD's ponatinib and AP26113 study presented at AACR meeting

Scientists use DNA sequencing to identify 'driver' mutations in cancer

Study confirms link between breast cancer and autoimmune arthritis

Galeterone safe, effective for patients with CRPC

Combination of cixutumumab and temsirolimus shrinks tumors in patients with Ewing's sarcoma

Platelet activating factor plays a crucial role in development of graft-versus-host disease

STAT-1 and PLSCR-1 proteins could play a crucial role in breast cancer

Achieving and maintaining ISO/IEC 27001 and BS 10012 certifications

Expanding research and clinical options for children with cancer

Examining how pain could play a direct protective role in the gut

Latest News